Your browser doesn't support javascript.
loading
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Sharma, Preeti; Marada, Venkata V V R; Cai, Qi; Kizerwetter, Monika; He, Yanran; Wolf, Steven P; Schreiber, Karin; Clausen, Henrik; Schreiber, Hans; Kranz, David M.
Afiliação
  • Sharma P; Department of Biochemistry, Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801; sharma39@illinois.edu d-kranz@illinois.edu.
  • Marada VVVR; Department of Biochemistry, Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • Cai Q; Department of Biochemistry, Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • Kizerwetter M; Department of Biochemistry, Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • He Y; Department of Pathology, Committee on Immunology, University of Chicago, Chicago, IL 60637.
  • Wolf SP; Department of Pathology, Committee on Immunology, University of Chicago, Chicago, IL 60637.
  • Schreiber K; Department of Pathology, Committee on Immunology, University of Chicago, Chicago, IL 60637.
  • Clausen H; Copenhagen Center for Glycomics, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Schreiber H; Department of Pathology, Committee on Immunology, University of Chicago, Chicago, IL 60637.
  • Kranz DM; Department of Biochemistry, Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801; sharma39@illinois.edu d-kranz@illinois.edu.
Proc Natl Acad Sci U S A ; 117(26): 15148-15159, 2020 06 30.
Article em En | MEDLINE | ID: mdl-32541028
ABSTRACT
The potency of adoptive T cell therapies targeting the cell surface antigen CD19 has been demonstrated in hematopoietic cancers. It has been difficult to identify appropriate targets in nonhematopoietic tumors, but one class of antigens that have shown promise is aberrant O-glycoprotein epitopes. It has long been known that dysregulated synthesis of O-linked (threonine or serine) sugars occurs in many cancers, and that this can lead to the expression of cell surface proteins containing O-glycans comprised of a single N-acetylgalactosamine (GalNAc, known as Tn antigen) rather than the normally extended carbohydrate. Previously, we used the scFv fragment of antibody 237 as a chimeric antigen receptor (CAR) to mediate recognition of mouse tumor cells that bear its cognate Tn-glycopeptide epitope in podoplanin, also called OTS8. Guided by the structure of the 237 FabTn-OTS8-glycopeptide complex, here we conducted a deep mutational scan showing that residues flanking the Tn-glycan contributed significant binding energy to the interaction. Design of 237-scFv libraries in the yeast display system allowed us to isolate scFv variants with higher affinity for Tn-OTS8. Selection with a noncognate human antigen, Tn-MUC1, yielded scFv variants that were broadly reactive with multiple Tn-glycoproteins. When configured as CARs, engineered T cells expressing these scFv variants showed improved activity against mouse and human cancer cell lines defective in O-linked glycosylation. This strategy provides CARs with Tn-peptide specificities, all based on a single scFv scaffold, that allows the same CAR to be tested for toxicity in mice and efficacy against mouse and human tumors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Antígenos Glicosídicos Associados a Tumores / Receptores de Antígenos Quiméricos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Antígenos Glicosídicos Associados a Tumores / Receptores de Antígenos Quiméricos Idioma: En Ano de publicação: 2020 Tipo de documento: Article